Is JDRF Global?
JDRF is the only global organization with a strategic plan to bring those living with T1D a continuous flow of life-changing therapies and, ultimately, a cure for the disease. JDRF’s highest priority remains funding research to deliver a cure for T1D and its complications.
Who is the CEO of JDRF?
Aaron J. Kowalski
Aaron J. Kowalski, Ph. D. As CEO of JDRF, a global leader in type 1 diabetes (T1D) research, Dr.
Is JDRF a company?
JDRF is the world’s largest nonprofit funder of type 1 diabetes research.
How much money does JDRF raise?
Through our advocacy and research leadership, JDRF influences and attracts others to support funding for cures and improving lives. In fiscal year 2021, we drew $425.7M in additional funding and investments for T1D therapy research and development from partners in the private and public sectors.
Who is the policy leader for JDRF?
As the policy leader for JDRF, Dr. Kowalski regularly advises members of Congress and leaders of the U.S. Department of Health and Human Services and U.S. Food and Drug Administration on issues surrounding access to T1D therapies and regulatory frameworks that promote innovation.
What is JDRF Global Mission Board?
He earned his doctorate in microbiology and molecular genetics from Rutgers University. The Global Mission Board is a group of national volunteer leaders who accelerate JDRF’s mission progress through special initiatives. We value your privacy.
What is JDRF doing to help people with Type 1 diabetes?
As CEO of JDRF, a global leader in type 1 diabetes (T1D) research, Dr. Kowalski drives strategies to accelerate progress toward cures — and simultaneously advance breakthroughs that enable people with T1D to live longer, healthier lives.
What is the JDRF CGM trial?
Kowalski led the landmark JDRF CGM Trial, published in the New England Journal of Medicine, that prompted private and government insurers to cover continuous glucose monitoring, opening up access to this critical technology.